IL-17 inhibitors for psoriasis.

IL-17 inhibitors for psoriasis.
Semin Cutan Med Surg. 2018 Sep;37(3):148-157
Authors: Paek SY, Frieder J, Kivelevitch D, Menter MA
Abstract
The role of the Th17/interleukin (IL)-23 pathway has been well elucidated in psoriasis. The IL-17 family includes 6 cytokines: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F. Two monoclonal antibodies targeting IL-17A (secukinumab, ixekizumab) and one antibody against the IL-17 receptor (brodalumab) have been approved for the treatment of moderate-to-severe plaque psoriasis. Clinical efficacy, safety, and tolerability of each agent is reviewed.
PMID: 30215631 [PubMed - in process]

Source: Seminars in Cutaneous Medicine and Surgery - September 16, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research